Baseline characteristics of SWEFOT patients with radiographic data
| All* (n=311) | In model† (n=269) | |
|---|---|---|
| Male, n (%) | 87 ((28%) | 75 (28%) |
| Age, years, median (IQR) | 57 (46–64) | 57 (46–63) |
| Cigarette smoking status | ||
| Current smokers, n (%) | 65 (24%) | 64 (24%) |
| Past smokers, n (%) | 104 (37%) | 100 (37%) |
| Never smokers, n (%) | 106 (39%) | 105 (39%) |
| Symptom duration, months, median (IQR) | 5 (4–8) | 6 (4–9) |
| RF positive, n (%) | 208 (67%) | 179 (67%) |
| Anti-CCP antibody positive, n (%) | 180 (61%) | 156 (62%) |
| RF and anti-CCP positive, n (%) | 146 (50%) | 125 (49%) |
| Sharp van der Hejde score, median (IQR) | 2 (0–6) | 2 (0–6) |
| Joint space narrowing score, median (IQR) | 0 (0–3) | 0 (0–3) |
| Erosion score, median (IQR) | 0 (0–2) | 0 (0–2) |
| Erosions, n (%) | 128 (41%) | 114 (42%) |
| Concurrent prednisolone, n (%) | 42 (14%) | 35 (13%) |
| Concurrent NSAIDs, n (%) | 192 (62%) | 171 (64%) |
| HAQ score, median (IQR) | 1.1 (0.8–1.6) | 1.1 (0.9–1.6) |
| DAS28, median (IQR) | 5.8 (5.0–6.4) | 5.8 (5.0–6.4) |
| 28-Swollen joint count, median (IQR) | 10 (6–14) | 10 (6–14) |
| 28-Tender joint count, median (IQR) | 8 (5–13) | 8 (5–13) |
| C-reactive protein, median (IQR) | 19 (9–46) | 19 (9–47) |
| Erythrocyte sedimentation rate, median (IQR) | 34 (22–54) | 35 (22–54) |
| VAS–patient global health, median (IQR) | 59 (40–74) | 59 (41–74) |
| VAS–pain, median (IQR) | 59 (42–73) | 60 (44–73) |
| Shared epitope, n (%) | 208 (74%) | 177 (73%) |
*In the whole group/multivariable model, missing numbers were as follows: RF, n=2/2; anti-CCP, n=16/14; smoking status, n=36/0; shared epitope, n=28/25; HAQ score, n=7/0; VAS scales, n=3/0; symptom duration, n=1/0.
†Multivariable model shown in table 2. There were no significant differences compared to the whole group.
Anti-CCP, anti-cyclic citrullinated peptide; DAS28, 28-joint disease activity score; HAQ, Health Assessment Questionnaire; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; VAS, visual analog scale.